Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Conditions
Interventions
Rilotumumab
Placebo
+3 more
Locations
189
United States
Research Site
Tucson, Arizona, United States
Research Site
Aurora, Colorado, United States
Research Site
Pueblo, Colorado, United States
Research Site
Chicago, Illinois, United States
Research Site
Baltimore, Maryland, United States
Research Site
Woodbury, Minnesota, United States
Start Date
October 1, 2012
Primary Completion Date
November 1, 2014
Completion Date
August 1, 2015
Last Updated
February 9, 2016
NCT06464978
NCT04704661
NCT04550494
NCT05489211
NCT05702229
NCT04674267
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions